Showing results (21-30 of 53) with videos related to
Sort By:
Pageof 6
Clinical Pharmacology and Therapeutics|December 14, 2004
Mechanism-based models for topotecan-induced neutropeniaFrédéric Léger, Walter J Loos, Roland Bugat, et al.The Oncologist|September 4, 2007
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?Ron H J Mathijssen, Floris A de Jong, Walter J Loos, et al.Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2010
Cisplatin-induced downregulation of OCTN2 affects carnitine wastingCynthia S Lancaster, Chaoxin Hu, Ryan M Franke, et al.Anti-Cancer Drugs|August 21, 2002
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxelWalter J Loos, Janos Szebeni, Albert J ten Tije, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area valuesWalter J Loos, Felix E de Jongh, Alex Sparreboom, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic studyFrederike K Engels, Walter J Loos, Jessica M van der Bol, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2010
Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute, Alex Sparreboom, Herman Burger, et al.Clinical Pharmacology and Therapeutics|April 30, 2004
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxelFrederike K Engels, Albert J Ten Tije, Sharyn D Baker, et al.Journal of Pharmaceutical and Biomedical Analysis|August 30, 2011
Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometryLisette Binkhorst, Ron H J Mathijssen, Inge M Ghobadi Moghaddam-Helmantel, et al.Pageof 6